Washington, DC - Ten new research awards totaling nearly $4 million will allow researchers to study possible links between gut microflora and the transformation of dietary compounds into substances known as metabolites, which are made or used when the body breaks down food, drugs, or chemicals. This process creates energy and the materials needed for growth, reproduction, and maintaining health; it also helps to eliminate toxic substances. Small, gut-derived metabolites may ultimately serve as a way to explain the widely acknowledged health benefits of diets high in fruits and vegetables. The awards will be funded by the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health.

New York - More than three in four U.S. employees (76 percent) have dealt with issues negatively affecting their mental health according to new survey results. Almost all employees (96%) agree that mental health is as important as physical health, according to a nationwide survey commissioned by the American Heart Association CEO Roundtable.

Washington, DC - The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.

Washington, DC - During National Breast Cancer Awareness Month, we recognize the women and men who courageously fight to survive, detect, treat, prevent, and support survivors of this devastating disease.  Our Nation vows to honor the loving memory of those lost to this disease, and we pray for their grieving families.  We reaffirm our ongoing commitment to defeat breast cancer through education, early detection, and innovative research.

Washington, DC - The U.S. Food and Drug Administration approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

Washington, DC - Uniformed Services University of the Health Sciences, Federal University of Rio de Janeiro, and Professor Joaquim Amorim Neto Research Institute in Campina Grande, Brazil. The enzyme, adenylate cyclase, is required to make cyclic adenosine monophosphate (cAMP), which plays a role in placental development and other cellular processes, including the immune response to infection. The findings appear in the Journal of Internal Medicine.